Trials / NCT00407602
Argus® II Retinal Stimulation System Feasibility Protocol
Completed N/A Retinal implant
- Sponsor
- Second Sight Medical Products
- Treatment
- Implant of Argus II Retinal Prosthesis
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 30 participants
- Started
- 2006-09
- Main results expected
- 2019-12-31
- Results posted
- Yes
- Record last updated
- 2022-01-20
What the study is testing
Investigational Phase of the Study:
The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis pigmentosa.
Post-Approval Phase of the Study:
To collect post-approval data in order to monitor the ongoing safety and reliability of the Argus II System
Where it runs
France (1)
- Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12, Paris
Mexico (1)
- Puerta de Hierro, Centro Medico, Centro de Retina, Zapopan, Jalisco
Switzerland (1)
- Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205, Geneva
United Kingdom (2)
- Moorfields Eye Hospital, Vitreoretinal Research Unit, London
- Manchester Royal Eye Hospital, Manchester
United States (7)
- Doheny Eye Institute, Los Angeles, California
- University of California San Francisco, San Francisco, California
- Johns Hopkins, Wilmer Eye Institute, Baltimore, Maryland
- Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute, New York, New York
- University of Pennsylvania, Scheie Eye Institute, Philadelphia, Pennsylvania
- Wills Eye Hospital, Philadelphia, Pennsylvania
- Retina Foundation of the Southwest, Dallas, Texas